Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2387904.
doi: 10.1080/21645515.2024.2387904. Epub 2024 Oct 28.

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020

Li Sun  1 , Shifan Wang  1   2 , Yafei Wang  1 , Yihan Wang  1 , Jinghui Wang  1 , Jing Li  1 , Xiaomeng Xu  1 , Junmian Zhang  1 , Yanli Cong  1 , Yu Guo  1
Affiliations

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020

Li Sun et al. Hum Vaccin Immunother. .

Abstract

The aim of this study was to analyze the incidence and characteristics of adverse events following immunization (AEFI) with post-licensure vaccines used in Hebei province from 2018 to 2020 and to evaluate the safety of vaccines. All information of AEFI was gained from national adverse event following immunization surveillance system (NAEFISS) in Hebei Province from 2018 to 2020. Descriptive epidemiology method was used to analyze the data about AEFI in Hebei province. Reporting rates of AEFI were calculated by sex, age, city, categories of AEFI, severity of AEFI, reaction categories, etc. A total of 35,999 AEFI were reported through NAEFISS, and the average annual rate was 47.64/100,000 doses. The reporting rates of common adverse reactions and rare adverse reactions were 46.37/100,000 doses and 1.05/100,000 doses. The male-to-female ratio was 1.26:1. Most of the AEFI were concentrated in the ≤1 year age group and were reported in the second quarter and third quarter. The majority of AEFI were reported to be recovered or improved, and about 62% of the AEFI occurred within 24 hours after vaccination. Vaccines associated with the highest reporting rate of AEFI were diphtheria, tetanus and acellular pertussis combined vaccine (DTaP, 170.45/100,000 doses). The reporting rate of allergic rash was found to be the highest in the adverse reactions (0.29/100,000 doses). The majority of AEFI cases were common adverse reactions, while serious rare adverse reactions caused by vaccines were extremely uncommon, and all vaccines used in Hebei Province were safe.

Keywords: Adverse events following immunization; incidence of adverse events following immunization; safety; surveillance; vaccine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Hinman AR, Orenstein WA, Schuchat A.. Centers for disease, control prevention. Vaccine-preventable diseases, immunizations, and MMWR: 1961-2011. MMWR Surveill Summ. 2011;60:49–9. - PubMed
    1. Yezli S, Gautret P, Assiri AM, Gessner BD, Alotaibi B. Prevention of meningococcal disease at mass gatherings: lessons from the Hajj and Umrah. Vaccine. 2018;36(31):4603–4609. doi:10.1016/j.vaccine.2018.06.030. - DOI - PubMed
    1. Adams LG, Khare S, Lawhon SD, Rossetti CA, Lewin HA, Lipton MS, Turse JE, Wylie DC, Bai Y, Drake KL, et al. Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development. Vaccine. 2011;29(41):7197–7206. doi:10.1016/j.vaccine.2011.05.080. - DOI - PMC - PubMed
    1. Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccin Immunother. 2021;17(10):3823–3830. doi:10.1080/21645515.2021.1939621. - DOI - PMC - PubMed
    1. Pan X, Lv H, Liang H, Wang Y, Shen L, Chen F, Chen Y, Hu Y. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. Hum Vaccin Immunother. 2022;18(1):2021711. doi:10.1080/21645515.2021.2021711. - DOI - PMC - PubMed

MeSH terms